(2) Since the survival stats of 30 months matches their previous stats for general HCC, it's not what you think it is. Target population is HCC. It's a target POPULATION. Duh lol
(3) The FDA definition of TPS = objective tumor progression aka local.
(4) You're not going to find a quote from management on 12 months and PFS because it doesn't exist and could not exist because management would never make such a silly claim.
Letter from CEO on general HCC stats. Note the bold:
Liver cancer is being described as a future epidemic in many populations and, as such, it is critical that the HEAT Study provide a rigorous data set to support ThermoDox's broad, global use. The incidence of primary liver cancer today is approximately 26,000 to 28,000 cases per year in the United States, approximately 40,000 cases per year in Europe and is rapidly growing worldwide at approximately 750,000 cases per year, due to the high prevalence of Hepatitis B and C in developing countries. By 2020, the World Health Organization estimates that primary liver cancer may become the #1 cancer worldwide, surpassing lung cancer.
The global importance of establishing an effective treatment for primary liver cancer cannot be overstated. Clinical outcomes in this disease remain poor, with the 5-year survival rate at less than 10 percent and median survival from time of diagnosis at approximately 30 months. Cure, usually through surgery, is possible in fewer than 20 percent of patients.
News 
Market Data 
Discover 
AI
